Table 3 summarizes the mean DSS and OS for patients categorized by individual and combined expression of NANOG and SOX2 in the total cohort of 348 HNSCC patients, or the subgroups of oropharyngeal tumors (n = 229), hypopharyngeal tumors (n = 60), and laryngeal tumors (n = 59). This evidence concerns the gene NANOG and head and neck squamous cell carcinoma.